News headlines about Integra Lifesciences (NASDAQ:IART) have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Integra Lifesciences earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the life sciences company an impact score of 46.3167379351658 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Integra Lifesciences (NASDAQ IART) traded down $0.73 during mid-day trading on Tuesday, reaching $49.84. 365,180 shares of the company traded hands, compared to its average volume of 646,400. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. Integra Lifesciences has a 1 year low of $40.51 and a 1 year high of $56.42. The company has a market cap of $3,968.60, a PE ratio of 81.70, a PEG ratio of 1.63 and a beta of 0.65.
Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.47 by ($0.02). Integra Lifesciences had a return on equity of 16.35% and a net margin of 4.52%. The company had revenue of $278.83 million during the quarter, compared to the consensus estimate of $286.00 million. During the same quarter last year, the firm earned $0.93 EPS. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. equities research analysts anticipate that Integra Lifesciences will post 1.85 earnings per share for the current year.
In other Integra Lifesciences news, Director Barbara B. Hill bought 10,768 shares of the company’s stock in a transaction on Tuesday, October 31st. The stock was bought at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the transaction, the director now owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total transaction of $70,785.00. Following the sale, the vice president now owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The disclosure for this sale can be found here. Insiders own 21.50% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.